Perrigo (PRGO) Retained Earnings (2013 - 2026)
Perrigo's (PRGO) quarterly Retained Earnings came in at -$3.0 million in Q1 2026, up 99.87% year-on-year from -$1.5 million in Q1 2025, and up 99.92% on a QoQ basis from -$3.7 billion in Q4 2025.
Perrigo (PRGO) Retained Earnings (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Retained Earnings data on file, last reported at -$3.0 million in Q1 2026.
- On a quarterly basis, Retained Earnings rose 99.87% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$3.0 million, a 99.87% increase from a year earlier, with the FY2025 full-year figure at -$3.7 billion, down 63.29% from the prior year.
- Retained Earnings for Q1 2026 stood at -$3.0 million, up from -$3.7 billion in the prior quarter.
- Over the last five years, Retained Earnings for PRGO reached as high as $75.0 million in Q2 2025 and fell as low as -$3.7 billion in Q4 2025.
- Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$2.1 billion in 2022.
- Across the five-year window, Retained Earnings tumbled 13904.0% in 2023 and soared 238.38% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$2.1 billion in 2022, then declined by 0.61% to -$2.1 billion in 2023, then declined by 8.26% to -$2.3 billion in 2024, then plunged by 63.29% to -$3.7 billion in 2025, then soared by 99.92% to -$3.0 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$3.0 million in Q1 2026, -$3.7 billion in Q4 2025, and -$2.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -3.00 Mn |
| Dec 31, 2025 | -3.68 Bn |
| Sep 27, 2025 | -2.26 Bn |
| Jun 28, 2025 | 75.00 Mn |
| Mar 29, 2025 | -2.26 Bn |
| Dec 31, 2024 | -2.25 Bn |
| Sep 28, 2024 | -2.21 Bn |
| Jun 29, 2024 | -54.20 Mn |
| Mar 30, 2024 | -2.08 Bn |
| Dec 31, 2023 | -2.08 Bn |
| Sep 30, 2023 | -2.05 Bn |
| Jul 1, 2023 | 19.90 Mn |
| Apr 1, 2023 | -2.07 Bn |
| Dec 31, 2022 | -2.07 Bn |
| Oct 1, 2022 | -2.04 Bn |
| Jul 2, 2022 | -146.80 Mn |
| Apr 2, 2022 | 15.00 Mn |
| Dec 31, 2021 | 35.50 Mn |
| Oct 2, 2021 | 54.20 Mn |
| Jul 3, 2021 | -1.88 Bn |